Digital medicine company Proteus Digital Health has raised an additional $52 million from undisclosed investors following a whopping $120 million raise the company announced just last month. That brings Proteus' latest round of funding -- its seventh -- to $172 million. By our count the company's total known funding is now close to $400 million, which makes it one of the most-funded, private...
Redwood City, California-based Proteus Digital Health announced plans this week to open its first international digital medicine manufacturing plant in the United Kingdom along with partnerships with various arms of the UK's National Health Service (NHS) to validate its "smart pill" system. The NHS-affiliated groups that inked partnerships with Proteus this week include Eastern Academic Health...
Proteus Biomedical's Raisin system
Proteus Digital Health, formerly known as Proteus Biomedical, has become the first company to receive Food and Drug Administration clearance for an ingestible biomedical sensor that monitors medication adherence.
The FDA granted 510(k) premarket approval to the Proteus Ingestible Event Marker (IEM) as a de novo medical device, meaning that there was no similar...
Proteus Biomedical's Raisin system, which Helius is based on.
UK-based retail pharmacy chain Lloydspharmacy has inked an exclusive deal with Proteus Biomedical to launch Proteus' first commercial product, Helius, an offering that includes sensor-enabled pills, a peel-and-stick sensor patch worn on the body, and a mobile health app. The patch records when a pill is ingested, tracks sleep patterns...
Proteus Biomedical announced today that it has received a patent for its ingestible biomedical sensor -- what the company has referred to as "intelligent medicine" in the past and what many have referred to as a "chip in a pill." The patent announcement also included new information about Proteus' partners: While the Novartis relationship had been previously announced, the company said it was...
Last June, when I was affiliated with, ahem, a competing publication, I publicly chided the World Economic Forum for shutting the press out of its first-ever mobile healthcare event. “It seems as if the industry is in danger of being co-opted by the business community's elites, possibly to the detriment of small entrepreneurs, consumers and the spirit of transparency,” I wrote.
It took a lot of...
Within the next 18 months, Novartis plans to seek regulatory approval for Proteus Biomedical's microchipped pills, which tracks medication adherence by time-stamping the patients ingestion of medications. Novartis global head of development Trevor Mundel told attendees at the recent Reuters Health Summit in New York that it will submit the smart pill system for regulatory approval in Europe...
Zucker Hillside Hospital in Glen Oaks, New York is working with Proteus Biomedical to pilot the "intelligent medicine" company's edible sensor for certain mental illnesses, according to a report from Scientific American.
"We're interested in determining patients' sleep patterns," John Kane, head of schizophrenia research at Zucker Hillside Hospital in Glen Oaks, N.Y. Kane. "For certain mental...
According to a report in the Economist, pharmaceuticals company Novartis' $24 million investment in intelligent medicine startup Proteus Biomedical may be just as important in the long run as Novartis' $50 billion takeover of eye-care firm, Alcon. Proteus Biomedical's venture capital round actually brought in $25.4 million, which makes us wonder if the difference came from an additional...
The global market for telecommunications is about $4 trillion to $4.5 trillion, Proteus Biomedical CEO Andrew Thompson noted during his presentation at TEDMED this week in San Diego. While there is this ongoing debate about healthcare reform, I noticed that there isn't a reform discussion taking place about technology markets, Thompson said. That's interesting, but it's important to know the...
